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Abstract
Background: Malignant melanoma is an exceptionally aggressive, drug-resistant and heterogeneous cancer. Recently it has
been shown that melanoma cells with high clonogenic and tumourigenic abilities are common, but markers distinguishing
such cells from cells lacking these abilities have not been identified. There is therefore no definite evidence that an exclusive
cell subpopulation, i.e. cancer stem cells (CSC), exists in malignant melanoma. Rather, it is suggested that multiple cell
populations are implicated in initiation and progression of the disease, making it of importance to identify subpopulations
with elevated aggressive properties.
Methods and Findings: In several other cancer forms, Aldehyde Dehydrogenase (ALDH), which plays a role in stem cell
biology and resistance, is a valuable functional marker for identification of cells that show enhanced aggressiveness and
drug-resistance. Furthermore, the presence of ALDH
+ cells is linked to poor clinical prognosis in these cancers. By analyzing
cell cultures, xenografts and patient biopsies, we showed that aggressive melanoma harboured a large, distinguishable
ALDH
+ subpopulation. In vivo, ALDH
+ cells gave rise to ALDH
2 cells, while the opposite conversion was rare, indicating a
higher abilities of ALDH
+ cells to reestablish tumour heterogeneity with respect to the ALDH phenotype. However, both
ALDH
+ and ALDH
2 cells demonstrated similarly high abilities for clone formation in vitro and tumour initiation in vivo.
Furthermore, both subpopulations showed similar sensitivity to the anti-melanoma drugs, dacarbazine and lexatumumab.
Conclusions: These findings suggest that ALDH does not distinguish tumour-initiating and/or therapy-resistant cells,
implying that the ALDH phenotype is not associated with more-aggressive subpopulations in malignant melanoma, and
arguing against ALDH as a ‘‘universal’’ marker. Besides, it was shown that the ability to reestablish tumour heterogeneity is
not necessarily linked to the more aggressive phenotype.
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Introduction
Malignant melanoma is an exceptionally aggressive type of
human cancer, known for its high metastatic potential and
notorious resistance against all major chemotherapeutic drugs.
The prognosis for metastatic melanoma patients is very poor: a
median survival of stage IV disease is only ,6 months with only
5% surviving 5 years [1,2]. Despite large efforts during the last
decades testing various treatment strategies, none significantly
prolonged patient survival [3], indicating that melanoma cells
possess efficient mechanism for developing resistance to therapy.
Recently it has been hypothesised that tumour initiation as well as
therapy resistance might be associated to the presence of cells with
stem cell properties, so called cancer stem cells (CSC) [4].
However, in malignant melanoma conflicting results have been
reported regarding the existence of such distinct CSC subpopu-
lations [5–7]. The recent study by Quintana et al. [7] revealed that
none of the tested surface markers for CSCs, identifying tumour-
initiating stem-like cells in other cancers, could distinguish between
tumourigenic and non-tumourigenic melanoma cells. Further-
more, the same study has shown that a large fraction, at least 25%
of random single cells isolated from melanoma patient biopsies,
had tumourigenic potential [7]. In agreement with this, recently
we have shown that 20–60% of randomly chosen (i.e. regardless
CSC marker expression) single melanoma cells, isolated from cell
cultures and xenografts, were highly clonogenic and self-renewing
[8]. Altogether, this opposes the CSC hypothesis claiming that
cells with tumourigenic properties are rare and distinguishable
from the tumour cells lacking such properties. Also, this suggests
that if the ‘‘markers’’ for discriminating cells with enhanced
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future, they will most likely mark a relatively large cell
subpopulation.
Lately, Aldehyde Dehydrogenase (ALDH), particularly its
isoform 1 has received considerable attention as a functional
marker for identification of cells with enhanced tumourigenic/
metastatic potential and elevated therapeutic resistance in several
cancers of epithelial origin [9–12]. ALDH is a detoxifying enzyme
responsible for the oxidation of intracellular aldehydes, thereby
mediating self-protection and resistance to some alkylating agents
used in cancer therapy [13]. Besides, ALDH is implicated in the
biology of normal stem cells through its role in metabolism of
retinol to retinoic acid, which initiates a program of cellular
differentiation [14]. Therefore, ALDH has been suggested as a
marker for isolating normal stem cells and lately also CSCs from
several tumour types (reviewed in [15]). Importantly, it has been
reported that the presence of cells with ALDH activity correlated
with poor clinical prognosis in breast and lung cancers [10,11,16].
However, in ovarian carcinoma, ALDH has been found to be a
favorable prognostic factor [17], suggesting that ALDH functions
as a ’’marker’’ of aggressive tumour cells in some contexts, but not
in others.
In malignant melanoma, the association between a biologically
aggressive phenotype and the presence of ALDH
+ cells has not
been studied. The aim of the present study was to investigate the
role of melanoma cells with ALDH activity for tumourigenicity
and therapeutic resistance. Our data indicate that despite the
presence of a large, clearly distinguishable subpopulation of
ALDH
+ cells, they did not demonstrate higher biological
aggressiveness compared to ALDH
2 cells. The latter observation
argues against ALDH as a marker for distinguishing tumour-
initiating and/or therapy-resistant cells in malignant melanoma.
ALDH
+ cells, therefore, may play a different role in melanoma
than in other cancers like epithelial cancers. In the absence of
clarified markers that can distinguish tumourigenic and therapy
resistant from nontumourigenic and sensitive cells, there is so far
lack of evidence that malignant melanoma is hierarchically
organized and follows a CSC model.
Materials and Methods
Ethics statement
Collection and the use of biopsies from metastatic
melanoma patients were approved by the South-East National
Committee for Medical and Health Research Ethics (REK,
approval no: S-01252 and 2.2007.997) and by the institutional
data protection official at Oslo University Hospital. The
written informed consent was obtained from all patients
involved in the study.
Metastatic melanoma models: cell cultures and
xenografts
To isolate tumour cells, patient biopsies were mechanically
disintegrated in cold PBS supplemented with 0.4% human serum
albumin. The melanoma cells were separated by magnetic beads
conjugated to the 9.2.27 antibody (9.2.27Ab) [18] (kindly provided
by Dr. R.Reisfeld, La Jolla, CA), which binds to the High
Molecular Weight-Melanoma-Associated Antigen (HMW-MAA)
expressed on tumour cells. Metastatic melanoma low-passage
cultures, Melmet 1 and Melmet 5, were established from
subcutaneous and lymph node (LN) metastases, respectively as
described previously [8]. Briefly, the isolated melanoma cells were
grown as traditional monolayers (MON) in RPMI medium
supplemented with 10% foetal calf serum (FCS) and 2 mM
Glutamax (both BioWittaker, Belgium) or as non-adherent
spheroids (SPH) in serum-free human embryonic stem cell
medium (hESCM) as described previously [5] in a 5% CO2
atmosphere at 37uC.
Melmet xenografts were established in nude mice by subcuta-
neous (s.c) injection of 50,000–250,000 cells derived from the
monolayer and the spheroid cultures of passages below 12.
Aldefluor assay and identification of cells with enhanced
ALDH activity
The Aldefluor kit (Stem Cell Technologies, Vancouver, BC,
Canada) was used to identify cell populations with high ALDH
enzymatic activity. Briefly, 10
6 cells harvested from cell cultures,
mechanically disintegrated xenografts or patient biopsies were
resuspended in Aldefluor assay buffer containing ALDH substrate
as recommended by the producer. As a negative control for all
samples, an aliquot of ‘‘Aldefluor-exposed’’ cells was immediately
quenched with a specific ALDH inhibitor, diethylaminobenzalde-
hyde (DEAB). Following 30 min incubation at 37uC, the cells were
centrifuged and processed as follows: a) cells derived from the
xenografts were resuspended in 100 ml Aldefluor buffer for the
subsequent staining with the APC-labelled TRA-1-85 antibody
(clone TRA-1-85, R&D Systems), which recognises human cells
and thereby allows their discrimination from mouse cells; b) cells
derived from patient biopsies were stained with the APC-labelled
9.2.27Ab, allowing identification of HMW-MAA expressing
tumour cells. After incubation for 30 min at 4uC and following
centrifugation, the cells were resuspended in cold Aldefluor buffer,
stained with 1 mg/ml propidium iodide (PI) (Sigma) to discrimi-
nate viable cells from dead cells during the following analysis on
LSRII or sorting on FACS DIVA flow cytometer (both from
Beckton Dickinson). Aldefluor staining was detected in a green
fluorescence channel FL1, and the samples treated with the
inhibitor DEAB (+DEAB) were used as controls to set the gates
defining the ALDH
+ region. The gating strategy is presented in
Figure S1. FlowJo 7.2.5 software was used to analyze the data.
Evaluation of clonogenicity of single melanoma cells
ALDH
+ and ALDH
2 cells were isolated from Melmet 1 and
Melmet 5 xenografts by FACS, distributing one viable cell per well
in hESCM into 96-well plate. The presence of single cells was
confirmed visually inspecting each well by a microscope shortly
after FACS. Each well was supplemented with fresh hESCM every
second day. After 3 weeks in culture, a number of wells containing
expanded clones (spheroids) was counted manually. To confirm
unlimited potential for self-renewal, the clones were disintegrated
by EDTA into single cells, which were replated at a clonal density
(1000 cells/ml hESCM) for evaluation of daughter spheroid
formation. Eventually, the cells constituting daughter spheroids
were reanalyzed by the Aldefluor assay.
Evaluation of tumourigenicity in vivo
Following FACS-isolation of ALDH
+ and ALDH
2 subpopula-
tions, an aliquot of the cell suspension was stained with trypan blue
to discriminate dead cells from viable cells, which were counted
using hemocytometer. The cells were resuspended at desired
concentrations in serum-free RPMI medium supplemented with
2 mM Glutamax and 20 mM Hepes before injection 100 ml s.c.
into NOD-SCID Il2rg
2/2 mice (strain NOD.Cg-Prkdc
scid
Il2rg
tm1Wjl/SzJ, 5–8 weeks of age).
Tumour formation was observed for up to 6 months measuring
tumour size weekly by a calliper. Tumour volume V was
calculated as follows: V=W
26L60.5, where W and L is tumour
ALDH in Melanoma
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involving animals were approved by the National Animal
Research Authority and were conducted according to the
regulations of the Federation of European Laboratory Animals
Science Association.
Immunohistochemical staining
Formalin-fixed paraffin-embedded sections of tumour tissue
from patient biopsies were subjected to immunohistochemical
staining with ALDH1A1 antibody (rabbit polyclonal, clone
ab51028, Abcam). In brief, after initial deparaffinization/hydra-
tion and antigen retrieval, the slides were incubated with the
ALDH1A1 antibody at dilution 1:300 in low pH buffer (Dako) for
1 h followed by incubation with a secondary antibody and
eventually visualization by using DakoCytomation EnVision+
System-HRP. Tumour tissue sections stained only with the
secondary antibody were used as negative controls, while human
liver sections stained with the primary followed by the secondary
antibody were used as a positive control.
Detection of TRAIL-R2 level by flow cytometry
The Melmet cells (,500,000) from monolayers were resus-
pended in 100 ml cold staining buffer (PBS containing 0.5% FCS
and 3% human immune globulin gammagard (N.V Baxter S.A,
Belgium) and stained with the primary antibody, mouse anti-
TRAIL-R2 (clone DJR2–4 (a.k.a.7–8), eBioscience) for 30 min at
4uC followed by staining with the secondary antibody, AlexaFluor
647-labeled goat anti-mouse (Invitrogen). The stained samples and
IgG isotype control samples were analyzed on LSRII flow
cytometer, and the data were analyzed by FlowJo software.
Therapy-related studies
For in vitro treatment of cells derived from the monolayer
cultures, 3,000 and 150,000 cells (comprising both ALDH
+ and
ALDH
2 subpopulations; the approximate percentage of each
population before treatment is indicated in Figure S2A, B) were
seeded into a well of 96-well and 6-well plates, respectively, and
the next day treated with 100 mg/ml dacarbazine (DTIC) (Medac,
Hamburg, Germany) or 10 mg/ml TRAIL-R2 agonist antibody
lexatumumab (formerly HGS-ETR2; provided by Human Ge-
nome Sciences, Rockville, MD). Two days later, the 96-well plates
were analyzed by CellTiter 96 Aqueous One solution, i.e. the
MTS assay (Promega, Madison, WI) to evaluate cell viability,
while the surviving cells from the 6-well plates were collected and
analyzed by the Aldefluor assay to identify the percentage of
ALDH
+ and ALDH
2 subpopulations after treatment. Untreated
cells and cells exposed to non-specific IgG (provided by Human
Genome Sciences) were used as controls and analyzed in parallel
with the treated samples.
To evaluate the treatment effect selectively on ALDH
+ and
ALDH
2 cells, the two subpopulations were FACS-isolated from
the monolayer cultures and the xenografts, resuspended in RPMI
medium and seeded into a 96-well plate for the MTS assay (3500–
5000 cells/well) or 6-well pate for the clonogenic-assay (500 cells/
well). Two days later, the cells were exposed to DTIC or
lexatumumab for two days (for evaluation of a short-term effect by
the MTS assay) or for two weeks (for evaluation of a long-term
effect by the clonogenic assay, where colonies were defined when
they contained .50 cells).
For in vivo treatment with DTIC, mice bearing Melmet tumours
(30–50 mm
3 in volume) were injected intraperitonally (i.p.) with
250 mg/kg DTIC. Three and five days later, the tumours were
harvested and analyzed by the Aldefluor assay.
Statistical analysis
To assess the statistical significance between ALDH
+ and
ALDH
2 groups, two-tailed Student’s t-test was done. Results were
considered statistically significant if p,0.05.
Results
Identification of ALDH-positive cells in metastatic
melanoma
Analysis of the Melmet 1 and Melmet 5 cultures (monolayers
and spheroids), the corresponding xenografts and melanoma
patient biopsies revealed the presence of ALDH
+ tumour cells. All
investigated Melmet cultures and xenografts harboured relatively
large ALDH
+ subpopulations, as illustrated by representative dot-
plots in Figure S2A,B. Although, the percentage of ALDH
+ cells
varied among the different models and specific samples, it was
observed that Melmet 1-based models usually had a larger fraction
of ALDH
+ cells (40–90%) than Melmet 5 models (8–20%). Also
the xenografts derived from directly implanted clinical biopsies, i.e.
omitting an in vitro culturing step, showed a large ALDH
+
subpopulation (,70%), (Figure S2C), confirming that the presence
of ALDH
+ cells in Melmet models is not a result of in vitro
culturing.
Cells with ALDH activity were also identified in patient
biopsies. The LN biopsies like #129, which contained melanoma
cells with high expression of HMW-MAA, harboured a large
ALDH
+ subpopulation in the HMW-MAA
positive fraction
(Figures 1A and S3). The biopsies like #135, which contained
melanoma cells with significantly lower expression of HMW-
MAA, had very few ALDH
+ cells in the HMW-MAA
positive
fraction (Figures 1A and S3). The same trend was observed in
several other investigated biopsies from lymph nodes of melanoma
patients (Figure S4). The HMW-MAA
negative fraction consisted
mainly of non-melanoma cells (‘‘normal’’ stromal cells), since there
were hardly any cells expressing a melanocytic marker Melan A in
this fraction (Figure S3). The HMW-MAA
negative cells did not
show a notable ALDH actvity (Figures S3 and S4). This indicates
that only HMW-MAA
high cells demonstrated high ALDH activity
in the investigated biopsies. To note, it has been shown by others
that HMW-MAA is related to a malignant potential in aggressive
melanoma [19].
Immunohistochemical analysis of archived clinical material
revealed ALDH expression in the biopsies from patients #1 and
#5. Thus ALDH1A1 was identified in the subcutaneous and the
LN metastases that were used for establishment of Melmet 1 and
Melmet 5 cultures, respectively. Furthermore, ALDH1A1 was
expressed also in the distant brain metastases and the primary
tumour taken from patients #1 and #5, respectively (Figure 1B).
The investigated biopsies from patient #1 and #5 were also
strongly positive for HMW-MAA as detected by the efficient
binding of 9.2.27Ab-magnetic beads as illustrated in Figure 1C.
All this confirms that aggressive melanoma clearly positive for
HMW-MAA also harbours ALDH
+ cells.
ALDH
+ and ALDH
2 cells are highly clonogenic in vitro
To compare the clonogenic abilities, ALDH
+ and ALDH
2
melanoma cells were FACS-isolated from the Melmet 1 and the
Melmet 5 xenografts, which contain a large and a considerably
smaller ALDH
+ subpopulation, respectively (Figure 2A). The
sorted single cells were cultured in hESCM one cell/well in 96-
well plates, and the clonogenic potential was evaluated by
counting expanded clones, spheroids (illustrated in the Figure 2D
insert). As shown in Figure 2D, a similar efficiency in spheroid
formation and growth rate was observed for the single cells from
ALDH in Melanoma
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+ cells in patient biopsies. (A) Flow cytometric analysis of cells from fresh LN biopsies stained by Aldefluor and
co-stained with APC-labelled 9.2.27Ab binding to HMW-MAA. Dot-plots show HMW-MAA staining (upper panel) and ALDH activity (lower panel) in
two representative biopsies #129 and #135, differing in the HMW-MAA levels and the ALDH activity. ‘‘Unstained controls’’ were used to set the gates
ALDH in Melanoma
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formed spheroids were disintegrated into single cells and further
cultured at a clonal density in hESCM. Efficient formation of
daughter spheroids was observed for both ALDH
+ and ALDH
2
groups (data not shown). Further analysis by the Aldefluor assay
revealed that the majority of the cells constituting the daughter
spheroids kept the ALDH phenotype of the parental cell, i.e. either
ALDH
+ or ALDH
2 (Figure 2B). This confirms that both
subpopulations had clonogenic abilities and could repopulate
themselves when cultured in hESCM for one month. When the
disintegrated spheroid cells were grown adherently in RPMI
medium with FCS (under ‘‘differentiation’’ conditions), ALDH
+
cells tended to reconstruct ALDH
2 subpopulation, but not vice
versa (Figure 2C).
ALDH
+ and ALDH
2 cells are equally tumourigenic in vivo
ALDH
+ and ALDH
2 subpopulations were isolated from
different xenografts and two patient biopsies, and the tumouri-
genic potential of the isolated cells was compared in vivo by s.c.
injection into NOD-SCID Il2rg
2/2 mice. As shown in Table 1
defining HMW-MAA
+ cells; ‘‘+DEAB controls’’ were used to set the gates defining ALDH
+ subpopulations in ‘‘2DEAB test samples’’. A supplementary
information regarding the analysis of these biopsies is presented in Figure S3. (B) ALDH immunostaining in the biopsies from patients #1 and #5:
subcutaneous and brain metastases (from #1); primary tumour and LN metastases (from #5). Bar, 100 mm. (C) A representative picture, here for the
biopsy from patient #1 (used for establishment of Melmet 1), illustrating 9.2.27Ab-magnetic beads binding to melanoma cells, which confirms HMW-
MAA positivity in the biopsy.
doi:10.1371/journal.pone.0010731.g001
Figure 2. In vitro comparison of clonogenic potential of ALDH
+ and ALDH
2 cells isolated from melanoma xenografts. (A) ALDH
+ and
ALDH
2 subpopulations identified in Melmet 1 and Melmet 5 xenografts. (B) Evaluation of the ALDH phenotype in the daughter spheroids formed
during culturing of sorted ALDH
+ and ALDH
2 cells in hESCM as described in (D). (C) Aldefluor analysis of the spheroid-derived cells subsequently
cultured adherently in RPMI for 2 weeks (representative dot-plots only for Melmet 5). (D) Sorted ALDH
+ and ALDH
2 cells were seeded one cell/well
and cultured in hESCM to allow formation of single-cell-derived clones, spheroids showed in the insert (bar, 100 mm). Efficiency of spheroid formation
from unsorted bulk melanoma cells is presented for comparison. Data represents mean 6 SEM (n=7). The formed spheroids from each group were
collected, disintegrated into single cells that were further cultured in hESCM for formation of daughter spheroids. The latter were reanalyzed by the
Aldefluor assay as shown in (B) or cultured further in RPMI as shown in (C).
doi:10.1371/journal.pone.0010731.g002
ALDH in Melanoma
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+ and ALDH
2 cells
derived from the xenografts were capable of efficient formation of
1
st generation tumours following injection of as few as 200 cells.
Also, the two subpopulations isolated from patient biopsies did not
show significant differences with respect to tumourigenic abilities:
1000 cells from ALDH
+ and ALDH
2 formed tumours at 7 of 12
Figure 3. In vivo tumour growth initiated by ALDH
+ and ALDH
2 cells isolated from Melmet 1 xenografts. (A) Sorted cells from both
subpopulations were injected s.c. (4000, 500 and 200 cells per injection, indicated in the figure) into NOD-SCID Il2rg
2/2 mice for formation of 1
st
generation tumours (appearance of the tumours is shown in the photographs). P.0.05 at all time points in the comparable groups. (B) The tumours
derived from ALDH
+ and ALDH
2 cells were resorted into ALDH
+/+, ALDH
+/2 and ALDH
2/2 subpopulations (see Figure 4), and 1000 viable cells from
each subpopulation were reinjected into mice for formation of 2
nd generation tumours. Data represent mean 6 SEM of 4–6 tumours. P.0.05
between ALDH
+/+ and ALDH
+/2;p ,0.05 between ALDH
+/+ and ALDH
2/2 indicated by *.
doi:10.1371/journal.pone.0010731.g003
Table 1. Efficiency of tumour formation (# tumours/# injections (%)).
Subpopulation # Cells injected **Transplanted
10,000 4,000 1,000 500 200
ALDH
+ 6/6 (100%) 4/4 (100%) 6/6 (100%) 4/4 (100%) 6/6 (100%)
ALDH
2 7/7 (100%) 4/4 (100%) 6/6 (100%) 4/4 (100%) 8/8 (100%)
*ALDH
+/+ 5/6 (83%)
*ALDH
+/2 4/6 (67%)
*ALDH
2/2 5/6 (83%)
*The harvested 1
st generation tumours formed from sorted ALDH
+ or ALDH
2 cells (the tumour growth curves are shown in Figure 3A) were FACS-separated into
positive and negative subpopulations, which were reinjected into mice for studies of the formation of 2
nd generation tumours (the tumour growth curves are shown in
Figure 3B).
**The 1
st generation tumours formed from the injected sorted ALDH
+ and ALDH
2 cells were transplanted into new mice for evaluation of the formation of 2
nd
generation tumours.
doi:10.1371/journal.pone.0010731.t001
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induce tumours (0/4) in both cases during 6 months in vivo.
Further characterization of 1
st generation tumours induced by
the ALDH
+ and ALDH
2 cells derived from the xenografts,
revealed that the tumour growth rate was not dependent (p.0.05)
on the ALDH phenotype (Figure 3A). Besides, it was shown that
the 1
st generation tumours derived either from ALDH
+ or
ALDH
2 cells can be serially passaged in vivo. Thus, following
transplantation, 2
nd generation tumours were generated with
100% efficiency in both cases (Table 1). Furthermore, ALDH
2
Figure 4. Identification of ALDH
+ and ALDH
2 subpopulations in 1
st and 2
nd generation tumours. Sorted viable ALDH
+ and ALDH
2 cells
from the Melmet 1 xenograft were injected s.c (the tumour growth curves are presented in Figure 3A), and the formed 1
st generation tumour were: i)
resorted into ALDH
+/+, ALDH
+/2, ALDH
2/2 subpopulations that were reinjected for formation of 2
nd generation tumours (the growth curves are
presented in Figure 3B); ii) divided into small peaces of tumour tissue that were transplanted for formation of 2
nd generation tumours. All formed
tumours were reanalyzed by the Aldefluor assay. The gates were set based on ‘‘+DEAB controls’’ (not shown).
doi:10.1371/journal.pone.0010731.g004
ALDH in Melanoma
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2 derived tumours (designated as
ALDH
2/2) could form 2
nd generation tumours with the same
efficiency and similar lag-time (40–47days) before palpability, as
ALDH
+ cells isolated from ALDH
+ derived tumours (designated as
ALDH
+/+) (Table 1). It should be noted that ALDH
2/2 tumours
demonstrated slower growth than ALDH
+/+ (p,0.05 at weeks
,10–12), whereas there was no statistically significant differences
(p.0.05) between ALDH
+/2 and ALDH
+/+ tumour growth
(Figure 3B). The latter observation suggests that tumours induced
by the ALDH negative subpopulations do not consistently show
slower growth than the tumours initiated by the positive
counterparts. Most important, Figure 3B reveals that the
ALDH
2/2 tumours also demonstrate unlimited growth, i.e. they
reach a diameter.10 mm, although with 2.5-weeks delay
compared to the ALDH
+/+ tumours.
To compare the capacity of the ALDH
+ and ALDH
2 cells to
reestablish tumour heterogeneity, the 1
st and 2
nd generation
tumours were harvested and reanalyzed by the Aldefluor assay to
elucidate their ALDH phenotype. The representative data is
shown in Figure 4. As can be seen, the tumours derived from
ALDH
2 cells basically kept the ALDH
2 phenotype (Figure 4, left/
middle branch, n=7), corresponding to the data in vitro
(Figure 2B,C). In contrast, ALDH
+ derived tumours had a mixed
phenotype, where 20–40% of the melanoma cells did not show
ALDH activity, whereas remaining 60–80% staid ALDH positive
(Figure 4, right branch, n=7) This confirms higher abilities of the
ALDH
+ cells to reestablish tumour heterogeneity, i.e. the existence
of ‘‘cellular hierarchy’’ with respect to ALDH.
ALDH phenotype and response to therapy
To evaluate whether ALDH
+ subpopulation is associated with
drug resistance, the response of ALDH
+ and ALDH
2 cells to two
different drugs was compared. The approved drug, an alkylating
agent dacarbazine (DTIC), and the experimental drug lexatumu-
mab were used. Lexatumumab is a fully human agonistic antibody
that specifically binds the death receptor TRAIL-R2, activating
the extrinsic apoptotic pathway [20]. Melmet 1 and Melmet 5 cells
in culture uniformly express TRAIL-R2 (Figure 5A), validating
these cell lines as potential targets of lexatumumab. The short-
term cytotoxic effect of the drugs is show in Figure 5B, revealing
that Melmet 5 responded moderately to treatment with DTIC,
while Melmet 1 was resistant; however, Melmet 1 showed higher
response to lexatumumab than Melmet 5.
To investigate whether ALDH
+ and ALDH
2 subpopulations
are differentially affected by the drugs, the percentage of each
subpopulation before and after the treatment was estimated as
indicated in Figure S5. Relative enrichment of one of the
subpopulation as a consequence of the treatment would indicate
enhanced treatment-resistance in this subpopulation. Previous
studies in other cancers indicated an association between drug-
resistance and ALDH
+ cells [11,12,21], therefore, the effect of
DTIC and lexatumumab primarily on the percentage of ALDH
+
cells was evaluated as shown in Figure 6 A, B. As can be seen, no
changes in the proportion of ALDH
+ cells were observed following
in vitro treatment with lexatumumab, whereas DTIC reduced the
percentage of ALDH
+ cells, consequently, increased the percent-
age of ALDH
2 cells (Figures 6A and S5A). Overnight-chase in
DTIC-free medium before the Aldefluor assay did not restore the
proportion of ALDH
+ cells (data not shown), implying an
irreversible effect on ALDH
+ subpopulation. However, in vivo
DTIC treatment of mice bearing Melmet tumours did not suggest
an elevated sensitivity of the ALDH
+ cells. Thus, the percentage of
ALDH
+ cells was not changed in the treated tumours compared to
untreated controls (Figures 6B and S5B), even though inhibitory
effect of DTIC on tumour growth/volume was documented
(Figure 5C).
To investigate the treatment effect selectively on ALDH
+ and
ALDH
2 cells, the two distinct subpopulations were FACS-isolated
from cell cultures and xenografts and exposed to the drugs in vitro.
The short-term and long-term effects of the treatment were
evaluated by the MTS and clonogenic assays, respectively. Both
subpopulations, isolated either from the cell culture (here we
analyzed only Melmet 5) (Figure 6C) or from different xenografts
(Figure 6D), demonstrated similar (p.0.05) viability when
evaluated by the MTS assay. Likewise, the clonogenicity of both
subpopulations appeared to be similar when the sorted cells were
cultured for two weeks in the presence of DTIC or lexatumumab.
After DTIC treatment, both subpopulations were capable forming
only small ‘‘colonies’’ harbouring less-than-50 cells, while
lexatumumab treatment completely blocked colony formation in
both subpopulations (data not shown). This indicates that
clonogenicity of both, ALDH
+ and ALDH
2 cells was strongly
inhibited by the prolonged treatments.
Summarising, neither of the two investigated drugs showed
higher cytotoxic effect on ALDH
2 compared to ALDH
+ cells,
suggesting that in examined malignant melanoma model systems,
the drug-response is not dependent on the ALDH
+ phenotype.
Seemingly higher sensitivity of ALDH
+ cells to DTIC in vitro,a s
detected by Aldefluor assay (Figure 6A), was not confirmed in vivo
(Figure 6B) or on sorted cells (Figure 6C, D), where similar
response of both subpopulations was observed.
Discussion
So far, there is no definite evidence that malignant melanoma
follows a CSC model, and there are no proved markers that would
distinguish tumourigenic from non-tumourigenic melanoma cells
[7]. However, this does not exclude a possibility that such markers
might exist, and if they do, they are expected to ‘‘mark’’ a large
subpopulation of cells, since clonogenic/tumourigenic melanoma
cells seem to exist at high frequencies [7,8]. Furthermore, there is a
possibility that markers might identify cell subpopulations showing
differences with respect to biological aggressiveness, including
therapeutic resistance. Identification of cell subsets that demon-
strate enhanced resistance to drugs would be of importance for
melanoma therapy. Also, it might help to uncover molecular
features associated with melanoma resistance.
Although, ALDH is not recognized as a generic marker of stem
cells [22], it appeared to be a valuable functional marker for
isolation of cells with tumour-initiating, metastatic and drug-
resistance properties in cancers that follow a CSC model, like
Figure 5. Evaluation of TRAIL-R2 levels and treatment effects in vitro and in vivo. (A) TRAIL-R2 levels. Solid lines, isotype-matched controls;
shaded areas, TRAIL-R2. (B) Cell viability (detected by the MTS assay) following in vitro treatment with 100 mg/ml DTIC or 10 mg/ml lexatumumab
(Lexa) for two days. Results are expressed as median cell survival relative to untreated control cells, and bars denote SEM from 2–6 independent
experiments (each performed in triplicate). (C) Relative tumour volume (normalized to the volume at day 0) in control and DTIC-treated mice. DTIC
(250 mg/kg) was injected i.p. at day 0 (indicated by an arrow), and the tumours were harvested at days 3 and 5 for detection of ALDH
+
subpopulations by the Aldefluor assay (as shown in Figure 6B). Data represent average volume (n=4 and n=8 for controls and treated groups,
respectively).
doi:10.1371/journal.pone.0010731.g005
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+ and ALDH
2 cells, derived from Melmet cultures (A, C) and xenografts (B, D), with regard to
response to treatment. (A) In vitro: the percentage of ALDH
+ and ALDH
2 cells in the control samples (untreated or IgG-treated, respectively) and
samples treated with 100 mg/ml DTIC or 10 mg/ml lexatumumab (Lexa) for two days, was determined by the Aldefluor assay as illustrated in the insert
and Figure S5A. The graphs show the treatment effect on the percentage of ALDH
+ cells only; error bars indicate SEM from 2–3 experiments.
*, p,0.05. (B) Melmet tumours were treated in vivo by injecting 250 mg/kg DTIC i.p. (effects on tumour growth is shown in Figure 5C), and the
percentage of ALDH
+ and ALDH
2 cells in control and treated tumours at day 3 (and day 5, not shown) was evaluated by the Aldefluor assay as
illustrated in the insert and Figure S5B. The percentages of ALDH
+ cells6SEM from 2–3 tumours are presented. (C, D) The ALDH
+ and ALDH
2 cells
were FACS-sorted from the culture (C) and the xenografts (D) and treated in vitro with DTIC or lexatumumab for two days before the MTS assay.
Results are expressed as median cell survival relative to untreated cells, and bars denote SD (single experiment performed in triplicate) (C) and SEM
from 2–3 independent experiments (D); p.0.05 in all compared groups, ALDH
+ versus ALDH
2.
doi:10.1371/journal.pone.0010731.g006
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examined melanoma models, a relatively large subpopulation of
cells had elevated activity of ALDH. Furthermore, ALDH activity
in melanoma patient biopsies seemed to correlate to expression of
the cell surface proteoglycan, melanoma associated antigen
HMW-MAA. HMW-MAA was shown to stimulate melanoma
cell growth, migration and epithelial-mesenchymal transition
promoting tumour progression [19]. Therefore, we reasoned that
ALDH might be a potentially interesting marker for identification
of melanoma cells with enhanced biological aggressiveness.
However, our present data indicate that there is no correlation
between ALDH activity and the clonogenic/tumourigenic capac-
ity, or enhanced drug-resistance, providing additional evidence
that ALDH is not a universal marker of aggressive tumourigenic
cells. Although melanomas showed heterogeneity with regard to
ALDH, both ALDH
+ and ALDH
2 cells could self-renew, form
clones in vitro and generate tumours that could be passaged in vivo.
The clonal spheroids generated from sorted single cells and grown
in stem cell medium, mainly retained the parental ALDH
phenotype, i.e. either ALDH
+ or ALDH
2 (Figure 2B), confirming
that: i) cell sorting definitely separated two distinct subpopulations;
ii) both subpopulations were intrinsically clonogenic. Also tumours
derived from ALDH
2 cells basically kept a parental ALDH
2
phenotype during two-three passages in vivo (Figure 4). This further
confirms that the observed tumourigenicity is a characteristic of
ALDH
2 cells, and not a result of poor separation of the two
subpopulations. In contrast, the tumours derived from ALDH
+
cells consisted of mixed subpopulations–a majority of the cells
were ALDH
+, whereas 20–40% did not show ALDH activity.
Altogether, this suggests that ALDH
+ cells have higher abilities to
reestablish tumour heterogeneity, at least with respect to ALDH.
There could be several reasons for this. If melanoma was
hierarchically organized and followed a CSC model, one could
speculate that ALDH
+ cells localize higher in the cellular
hierarchy, have stem cell characteristics and, therefore, can
recapitulate the phenotypic heterogeneity, which was not possible
for ALDH
2 cells. However, no other evidence indicating that
ALDH
+ cells are more CSC-like and thus more tumourigenic
compared to ALDH
2 were found. Therefore, the simplest
interpretation would be that some ALDH
+ cells lose the ALDH
activity under the influence of the in vivo microenvironment. Since
this activity does not seem to be crucial for tumour-formation,
both subpopulations could eventually contribute to the tumour
growth. It should be noted that recently Held et al. showed using
mouse melanoma cells, that the ability to reestablish heterogeneity
(in this case, with respect to CD34
+/2 p75
+/2 phenotype) not
necessarily correlates to the enhanced capacity of tumour/colony-
initiation [24], which is in agreement with our data.
Enhanced resistance to therapy is another characteristic of
ALDH
+ cells identified in cancers like breast and colorectal
cancers that seem to follow a CSC model [11,12,21]. In contrast,
no correlation between ALDH
+ subpopulation and therapeutic
resistance was observed in the examined melanoma models. It
should be mentioned that, unlike the classical chemotherapeutic
agent cyclophosphamide (a target of the ALDH1A1 enzymatic
activity), the drugs that we used (DTIC and lexatumumab) are not
substrates of ALDH. However, previous studies have reported a
correlation between ALDH
+ cells and enhanced resistance to
drugs that are not substrates of ALDH [11,12,21], indicating that
the therapeutic resistance was mediated by mechanism not related
to the ALDH enzymatic activity, but somehow activated in
ALDH
+ subpopulations. It has been speculated that these
mechanisms are associated with stemcellness of ALDH
+ cells
[12,21]. In highly aggressive melanoma, however, such mecha-
nisms do not seem to be restricted to ALDH
+ cells, since these cells
did not demonstrate higher resistance than ALDH
2 cells to the
investigated drugs. In contrast to the situations in other cancers,
[11,12,21], a reduction of the ALDH
+ fraction was observed
following DTIC treatment in vitro (Figure 6A), implying that
ALDH
+ cells might be more sensitive to DTIC. This, however,
was not confirmed in vivo (Figure 6B). Since none of our other
assays, or in vivo studies (Figure 6 B–D) confirmed that DTIC
preferentially ‘‘targets’’ ALDH
+ subpopulation, we assume that
both, ALDH
+ and ALDH
2 cells respond to DTIC and
lexatumumab similarly. The in vitro observed reduction of the
ALDH
+ proportion we explain by the DTIC-induced interference
with the Aldefluor assay, e.g. inhibition of the ALDH enzymatic
activity when the treatment was performed in vitro. Thus, the
therapy-related data further argues against ALDH as a marker of
melanoma cells with enhanced aggressive properties.
To conclude, malignant melanoma harbours a large fraction of
cells positive for ALDH. However, melanoma cells lacking ALDH
activity (ALDH
2) are equally resistant to treatment, equally
tumourigenic and can be serially transplanted in vivo like cells with
ALDH activity (ALDH
+). This indicates that in highly aggressive
melanoma, the functional ‘‘marker’’ ALDH does not discriminate
cells with enhanced biological aggressiveness, and ALDH
+
subpopulation does not play an exclusive role in tumour initiation
and/or in low response to therapy. Although, ALDH
+ melanoma
cells show higher abilities for generating phenotypic heterogeneity,
the implication of this remains unknown, and the present data
suggests that it is not associated with clonogenic and tumourigenic
differences nor with differences in drug-resistance. It should be
added that it has not been investigated whether ALDH activity
could be more discriminatory in less aggressive tumours or
primary melanomas. Here presented data, based on the melanoma
models and the patient biopsies that represent very aggressive
advanced-stage disease, can not exclude such possibility.
Supporting Information
Figure S1 Gating strategy for flow cytometry analysis of
Aldefluor-stained samples. Cells derived from disintegrated in vivo
samples were stained by the Aldefluor assay, followed by staining
with human specific anti-TRA-1-85. All samples were stained with
PI just before flow cytometry. All samples were analyzed by
sequential gating including main population (G1), single cells (G2),
viable (PI negative) cells (G3), TRA-1-85-positive (i.e. human) cells
(G4). Controls with DEAB inhibitor (‘‘+DEAB’’) were used to set a
gate G5, which helps to identify the ALDH
+ subpopulation in the
test samples without DEAB inhibitor (‘‘2DEAB’’).
Found at: doi:10.1371/journal.pone.0010731.s001 (0.67 MB TIF)
Figure S2 Identification of ALDH
+ subpopulations in various
melanoma models in vitro and in vivo. Representative dot-plots for
Melmet 1 (A) and Melmet 5 (B) monolayer cultures (MON),
spheroid cultures (SPH) and xenografts derived from the
corresponding MON and SPH (A, B). (C) Identification of the
ALDH
+ subpopulation in the xenograft established from directly
implanted patient LN biopsy. ‘‘+DEAB controls’’ were used to set
the gates defining ALDH
+ populations in ‘‘2DEAB’’ samples.
Found at: doi:10.1371/journal.pone.0010731.s002 (0.84 MB TIF)
Figure S3 Analysis of LN biopsies #129 and #135 (see also
Figure 1A) with respect to HMW-MAA expression and ALDH
activity. FACS analysis was performed following the strategy
described in Figure S1. The presence of melanoma cells in the
biopsies as well as in the sorted HMW-MAApositive, but not in
HMW-MAAnegative fractions, was confirmed by Melan A
ALDH in Melanoma
PLoS ONE | www.plosone.org 11 May 2010 | Volume 5 | Issue 5 | e10731staining (using the antibody clone A103 (Dako) at dilution 1:20;
DAPI for nuclear counterstain). Melan A staining-green, DAPI -
blue. HMW-MAA expression was identified by staining with
antibody 9.2.27-APC; median of fluorescence (Fl.) intensity in
HMW-MAA+ subpopulation is indicated in the histograms.
ALDH activity in HMW-MAApositive and HMW-MAAnegative
(where possible) fractions was analyzed by the Aldefluor assay.
Found at: doi:10.1371/journal.pone.0010731.s003 (3.53 MB TIF)
Figure S4 Analysis of the additional LN biopsies #127 and
#126 representing high and low expression of HMW-MAA,
respectively. The samples were analyzed as described in Figure S3.
The presence of melanoma cells in the biopsy was confirmed by
Melan A staining. Median of fluorescence (Fl.) intensity in HMW-
MAA
+ subpopulation is indicated in the histograms. ALDH
activity in HMW-MAApositive and HMW-MAAnegative (where
possible) fractions was analyzed by the Aldefluor assay.
Found at: doi:10.1371/journal.pone.0010731.s004 (1.74 MB TIF)
Figure S5 Treatment effect on ALDH
+ and ALDH
2 cells
derived from cultures (A) and xenografts (B). The treatment was
performed as described in Figure 6A, B, and the viable cells were
subjected to the Aldefluor assay. The gates were defined based on
‘‘+DEAB controls’’, and the ALDH
+ and ALDH
2 subpopulations
were identified in ‘‘2DEAB test samples’’. The percentages of
ALDH
+ and ALDH
2 cells are indicated in blue and black,
respectively.
Found at: doi:10.1371/journal.pone.0010731.s005 (1.72 MB TIF)
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